Martin Claussen

Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial

Jürgen Behr, Antje Prasse, Michael Kreuter et al. · The Lancet Respiratory Medicine · 2021 · 516 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +9

Anticoagulation and Survival in Pulmonary Arterial Hypertension

Karen M. Olsson, Marion Delcroix, Hossein Ardeschir Ghofrani et al. · Circulation · 2013 · 369 citations · Full text

Medicine, Cardiology, Clinical Sciences +11

Extrapulmonary Effects of Chronic Obstructive Pulmonary Disease on Physical Activity

Henrik Watz, Benjamin Waschki, Corinna Boehme et al. · American Journal of Respiratory and Critical Care Medicine · 2007 · 368 citations

Medicine, Physical Medicine, Exercise Testing +16

COMPERA 2.0: a refined four-stratum risk assessment model for pulmonary arterial hypertension

Marius M. Hoeper, Christine Pausch, Karen M. Olsson et al. · European Respiratory Journal · 2021 · 338 citations · Full text

Medicine, Cardiology, Pulmonology +14

Decreasing Cardiac Chamber Sizes and Associated Heart Dysfunction in COPD

Henrik Watz, Benjamin Waschki, Trhorsten Meyer et al. · CHEST Journal · 2010 · 279 citations

Medicine, Cardiology, Internal Medicine +14